BridgeBio Pharma
CA - Palo AltoPharmaceutical
Focus: BridgeBio Pharma is a Palo Alto-based pharmaceutical company focused on genetic disease treatments, particularly in rare diseases and oncology. The company has 62 active job openings and operates a clinical-stage pipeline with multiple programs in Phase 2-3 development.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Open Jobs
94+36 this month
Hot — 65 jobs added in 30d
Net +36 (65 new, 29 removed). Aggressive expansion phase.
Should You Work at BridgeBio Pharma?
AI assessmentStrong fit for professionals seeking growth-stage biotech exposure in rare genetic disease with an approved product and near-term catalysts, but financial opacity requires due diligence.
Why Work Here
- ATTRUBY (acoramidis) is an approved product with growth potential (LOE: 2039), providing revenue visibility and clinical validation
- Robust pipeline with 6 Phase 3 programs and 20 total active trials, particularly strong in amyloidosis and rare genetic diseases with clear regulatory pathways
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growth13.2yr
Only approved product providing near-term revenue foundation; positioned to capture multiple TTR-amyloidosis indications across Phase 3 pipeline.
Help build intelligence for BridgeBio Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.